Elsevier

Epilepsy Research

Volume 41, Issue 2, August 2000, Pages 163-167
Epilepsy Research

Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women

https://doi.org/10.1016/S0920-1211(00)00139-XGet rights and content

Abstract

A prospective cohort analysis of premenopausal women with focal epilepsy was conducted in order to determine whether polycystic ovary syndrome (PCOS) is a common finding in women treated with antiepileptic drugs (AED). This study was carried out in 93 of 150 women (aged between 20 and 53 years; mean, 34.3 years) with chronic focal epilepsy consecutively cared for at the Department of Epileptology, University of Bonn: 38 were receiving one AED (18 valproate, 20 carbamazepine), 36 more than one drug, and 19 were without medication. Patients were followed-up for 6 months. PCOS was defined as hyperandrogenism (testosterone concentration, >0.7 ng/ml) combined with oligomenorrhoea (cycle length, >35 days) or amenorrhoea. PCOS was identified in two out of 19 (10.5%) patients receiving no medication; in four of 38 (10.5%) of patients receiving monotherapy, and in none of the patients receiving more than one AED. The incidence of PCOS in patients treated with valproate monotherapy (11.1%) was similar to that in patients treated with carbamazepine (10%) and also to that in patients not treated with AEDs. The results of this study suggest that the manifestation of PCOS in women with focal epilepsy is not related to the administration of valproate or carbamazepine.

Introduction

Reproductive endocrine disorders are common in women with epilepsy. Not surprisingly, birth rate is statistically reduced in such patients (Wallace et al., 1998). Explanations given for this finding include the impact of epilepsy (Herzog et al., 1986, Drislane et al., 1994, Bauer, 1996, Herzog, 1997) and anticonvulsant drugs (AED) (Isojärvi et al., 1993), resulting in an increased rate of anovulatory cycles consequently causing sterility (Cummings et al., 1995, Bauer et al., 1998).

Recently, the impact of valproate (VPA) on reproductive endocrine disorders has been discussed (Isojärvi et al., 1993, Isojärvi et al., 1996, Isojärvi et al., 1997, Isojärvi et al., 1998). It has been suggested that polycystic ovaries (PCO) and/or hyperandrogenism is a finding often detected in women with epilepsy treated with VPA, the association being most common in women with a body mass index (BMI) greater than 25 kg/m2 (Isojärvi et al., 1993, Isojärvi et al., 1996). These findings are not substantiated by other studies (Murialdo et al., 1997), and are at odds with the world-wide clinical experience of those who have treated women with the drug over many years (Genton et al., 2000). PCO and hyperandrogenism do not necessarily indicate a clinically relevant abnormal condition. PCO is found in about 20% of the general population, and polycystic ovary syndrome (PCOS) in only 4% of women (Clayton et al., 1992, Farquhar et al., 1994). Similarly, in women with epilepsy, PCO is a fairly common finding, but fully-blown PCOS occurs less frequently (Herzog, 1997).

The currently accepted definition of PCOS is an ovulatory dysfunction with clinical evidence of hyperandrogenism and/or hyperandrogenaemia, and exclusion of related disorders, such as those affecting adrenal or thyroid function (Adams et al., 1985). This definition specifically excludes the finding of PCO, multifollicular ovaries or hyperandrogenism in isolation. In the clinical setting, ultrasonography of a sufficient standard is not widely available for the diagnosis of PCO (Fox et al., 1991). Furthermore, to lead to confusion, PCO as defined by ultrasonographic studies may be present in normal women with ovulatory cycles and no hirsutism (Polson et al., 1987, Franks, 1995). Measurement of different hormones have been found to be predictive of PCOS confirmed by sophisticated ultrasonography in a research setting. For example, in testing for raised testosterone or luteinizing hormone and follicular stimulating hormone levels, a positive result was associated with 100% accuracy in the diagnosis of PCOS in women with functional oligomenorrhoea or amenorrhoea (Fox et al., 1991).

Since our study was to diagnose PCOS, ultrasonography was considered unnecessary. A combination of clinical and laboratory assessments was used in the evaluation of women with epilepsy in order to determine whether AEDs were associated with an increased risk of PCOS.

Section snippets

Patients and methods

From 150 women with focal epilepsy treated as out-patients at the Department of Epileptology, University of Bonn, 93 patients were included into the study; the other 57 patients were excluded because of (a) oral contraceptives, (b) menopause or (c) extra-temporal focal epilepsy. The patients were consecutively enrolled and followed-up for 6 months to establish menstrual cycle rhythm. Chronic anticonvulsant medication was maintained during this period.

The 93 women (aged between 20 and 53 years;

Results

The patients were receiving none (19 patients) or one AED (VPA in 18 patients, with mean daily dosage 1414 mg; carbamazepine (CBZ) in 20 patients, with mean daily dosage 1447 mg) or were treated with AED polytherapy (36 patients) including VPA plus an enzyme-inducing AED (n=11), VPA plus a non-enzyme-inducing AED (n=5), two enzyme-inducing AEDs (n=2), two non-enzyme-inducing AEDs other than VPA (n=2), and enzyme-inducing plus non-enzyme-inducing AEDs other than VPA (n=16).

In 60 patients

Discussion

All the patients in this study had chronic focal epilepsy, the majority were receiving long-term treatment with AEDs. If focal epilepsy affects the hypothalamic–pituitary axis (i.e. increases the LH-pulse frequency), it may cause testosterone-related hyperandrogenism (Herzog, 1997). Since testosterone is metabolised in the liver and VPA is an enzyme inhibitor, it has been argued that treatment with VPA could elevate serum testosterone levels (Herzog, 1996). Conversely, treatment with CBZ might

Acknowledgements

We would like to thank Dr Iris Damm for her help in data sampling.

References (26)

  • R. Fox et al.

    The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests

    Clin. Endocrinol. (Oxford)

    (1991)
  • S. Franks

    Polycystic ovary syndrome

    N. Engl. J. Med.

    (1995)
  • Genton, P., Bauer, J., Duncan, S., Taylor, A.E., Balen, A.H., Eberle, A., Pedersen, B., Salas-Puig, X., Sauer, M.V.,...
  • Cited by (128)

    • Increased GABA transmission to GnRH neurons after intrahippocampal kainic acid injection in mice is sex-specific and associated with estrous cycle disruption

      2022, Neurobiology of Disease
      Citation Excerpt :

      Taken together, these studies suggest that seizure activity itself can increase susceptibility to reproductive endocrine comorbidities. In females, these comorbidities can take the form of polycystic ovary syndrome (Bauer et al., 2000; Herzog, 2008), menstrual cycle disruption (Herzog, 2008; Herzog et al., 2003; Zhou et al., 2012), and/or hormonal disruption (Herzog et al., 2003). In males, comorbidities such as semen abnormalities (Herzog et al., 1986b) and low serum testosterone (Talbot et al., 2008) are observed.

    • Pathological pulses in PCOS

      2019, Molecular and Cellular Endocrinology
    • Polycystic Ovary Syndrome and Hyperandrogenic States

      2019, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition
    View all citing articles on Scopus
    View full text